UNITED THERAPEUTICS Corp Quarterly Costs and Expenses in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
UNITED THERAPEUTICS Corp quarterly/annual Costs and Expenses history and growth rate from Q1 2010 to Q2 2024.
  • UNITED THERAPEUTICS Corp Costs and Expenses for the quarter ending June 30, 2024 was $395M, a 39.5% increase year-over-year.
  • UNITED THERAPEUTICS Corp Costs and Expenses for the twelve months ending June 30, 2024 was $1.35B, a 32.3% increase year-over-year.
  • UNITED THERAPEUTICS Corp annual Costs and Expenses for 2023 was $1.14B, a 19.4% increase from 2022.
  • UNITED THERAPEUTICS Corp annual Costs and Expenses for 2022 was $957M, a 15.3% decline from 2021.
  • UNITED THERAPEUTICS Corp annual Costs and Expenses for 2021 was $1.13B, a 27% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.35B $395M +$112M +39.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $1.24B $321M +$98.9M +44.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $1.14B $355M +$38.7M +12.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 $1.1B $282M +$80.7M +40% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-01
Q2 2023 $1.02B $283M +$18M +6.79% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $1.01B $223M +$48.6M +27.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $957M $316M +$70.5M +28.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $886M $202M -$14.3M -6.62% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $900M $265M +$40.8M +18.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $860M $174M -$270M -60.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $1.13B $245M -$74.2M -23.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $1.2B $216M +$57M +35.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $1.15B $224M +$2.8M +1.26% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $1.14B $444M +$254M +134% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $890M $320M +$72M +29.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-22
Q3 2020 $818M $159M -$59.1M -27.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $877M $222M +$69.3M +45.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $808M $190M -$829M -81.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $1.64B $248M -$2.3M -0.92% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $1.64B $218M -$45M -17.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 $1.68B $152M -$74.9M -33% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-29
Q1 2019 $1.76B $1.02B +$936M +1138% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-29
Q4 2018 $822M $250M -$75.8M -23.3% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-24
Q3 2018 $898M $263M +$141M +116% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-30
Q2 2018 $757M $227M -$129M -36.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-31
Q1 2018 $886M $82.3M -$24.6M -23% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q4 2017 $910M $326M +$90.9M +38.7% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $820M $122M -$47.9M -28.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-31
Q2 2017 $867M $356M +$229M +180% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 $639M $107M +$102M +1917% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-02
Q4 2016 $537M $235M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $170M Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-25
Q2 2016 $127M -$48M -27.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-07-27
Q1 2016 $5.3M -$337M -98.5% Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-26
Q2 2015 $1.05B $175M +$28.9M +19.7% Apr 1, 2015 Jun 30, 2015 10-Q 2016-07-28
Q1 2015 $1.02B $342M +$269M +367% Jan 1, 2015 Mar 31, 2015 10-Q 2016-04-28
Q4 2014 $750M $168M -$150M -47.2% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-22
Q3 2014 $899M $362M +$165M +83.3% Jul 1, 2014 Sep 30, 2014 10-Q 2015-10-27
Q2 2014 $735M $146M -$11.8M -7.47% Apr 1, 2014 Jun 30, 2014 10-Q 2015-07-28
Q1 2014 $747M $73.3M -$77.8M -51.5% Jan 1, 2014 Mar 31, 2014 10-Q 2015-04-28
Q4 2013 $824M $318M +$202M +176% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-25
Q3 2013 $622M $198M +$35.8M +22.2% Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-28
Q2 2013 $586M $158M +$38.3M +31.9% Apr 1, 2013 Jun 30, 2013 10-Q 2014-07-29
Q1 2013 $548M $151M +$53.6M +55% Jan 1, 2013 Mar 31, 2013 10-Q 2014-04-29
Q4 2012 $494M $115M -$16.5M -12.5% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-24
Q3 2012 $511M $162M +$63M +63.8% Jul 1, 2012 Sep 30, 2012 10-Q 2013-10-29
Q2 2012 $448M $120M +$50.7M +73.3% Apr 1, 2012 Jun 30, 2012 10-Q 2013-07-25
Q1 2012 $397M $97.5M -$28.2M -22.5% Jan 1, 2012 Mar 31, 2012 10-Q 2013-04-25
Q4 2011 $425M $132M -$13.7M -9.42% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-25
Q3 2011 $439M $98.8M -$7.32M -6.9% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-01
Q2 2011 $446M $69.3M -$4.24M -5.77% Apr 1, 2011 Jun 30, 2011 10-Q 2012-07-26
Q1 2011 $451M $126M +$29.1M +30.1% Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-26
Q4 2010 $422M $145M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-26
Q3 2010 $106M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-27
Q2 2010 $73.5M Apr 1, 2010 Jun 30, 2010 10-Q 2011-07-28
Q1 2010 $96.6M Jan 1, 2010 Mar 31, 2010 10-Q 2011-04-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.